Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
5 Worldwide Road Food varieties You Should Attempt - 2Make your choice for the sweet that transports you to its nation of beginning!
- 3What you need to know about flu treatments as cases spike across the US
- 4A 'rampaging lion' nebula roars to life in a stunning deep-space photo
- 5SpaceX launches Starlink satellites from California on 160th Falcon 9 flight of the year (video)
- Step by step instructions to Contrast Lab Jewels and Regular Ones
- Hilary Duff announces new album ‘Luck… or Something,’ her first in over 10 years: ‘Excited is the largest understatement’
- ‘Integral part of our nation’: Herzog visits Franciscan Sisters in Jerusalem ahead of Christmas
- The 10 Most Significant Games in History
- Courageous Climbing: Trails and Stuff for Outside Lovers
- 15 Preposterous Cosplay Ensembles That Will Blow You Away
- Violence 'never part' of break-in plan, court told
- Cyber Monday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- Finding Europe's Head Traveler Objections: An Excursion Through Famous Attractions
